CAMBRIDGE, Mass., Feb. 4, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
"This is an important period in Catabasis' development and we are fortunate to be adding someone with Ken's breadth of experience to our board of directors," said Michael Ross, Ph.D., chairman of Catabasis' board of directors. "Ken brings a track record of building and guiding successful public and private biotechnology companies. This experience will be indispensable to Catabasis as it completes three Phase 2 trials of its lead SMART Linker conjugate CAT-2003 in hypertriglyceridemias this year, and advances additional candidates based on its SMART Linker conjugation technology in dyslipidemias and inflammatory diseases."
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled an experienced team that is passionately committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.
Please visit www.catabasis.com for more information.
Catabasis Pharmaceuticals Inc.
Tony Russo, Ph.D.
Matt Middleman, M.D.
SOURCE Catabasis Pharmaceuticals Inc.